Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies.
OBJECTIVE
The presence of CD44 isoforms was evaluated in ascitic fluid and serum samples of patients with gynecologic malignancies. Previously, the shedding of tumor-associated cell surface antigens has been demonstrated in the blood and malignant effusions of gynecologic cancer patients. Thus, the shedding of CD44 was also studied in ascitic fluids and sera of these patients, to address variant isoform expression as a biomarker of gynecologic cancer.


METHODS
The expression of CD44 isoforms by ovarian tumor cells was examined by flow cytometry using variant-specific monoclonal antibodies. The release of these isoforms into the peripheral circulation and ascites was assayed by Western immunoblot analysis.


RESULTS
Flow cytometric analysis of ovarian tumor cell lines revealed a strong expression of CD44 with significant levels of v4/5 and v6 isoforms. The presence of circulating CD44 isoforms was detectable in the sera of six of eight cancer patients, as well as in 12 of 16 ascitic fluids. Of the CD44-positive specimens, all six positive sera expressed detectable levels of variant CD44. The CD44v6 was present in all of the positive sera samples tested. In the ascites, the "shed" CD44 appeared to be associated predominantly with shed particles (vesicles) of plasma membranes (membrane fragments). Of ten CD44-positive ascites samples, all expressed significant levels of variant CD44.


CONCLUSIONS
In addition to mediating metastasis, the differential expression and shedding of CD44 isoforms into the circulation may represent important determinants in the escape of tumors from immune surveillance, and their detection may be a diagnostic or prognostic marker.
Taylor
D D
DD
Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Kentucky, USA.
Gercel-Taylor
C
C
Gall
S A
SA
D000368:Aged; D000911:Antibodies, Monoclonal; D001202:Ascitic Fluid / Q000276:immunology; D014408:Biomarkers, Tumor; D015153:Blotting, Western; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis* / Q000097:blood; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology*; D011379:Prognosis; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018960:Hyaluronan Receptors